bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
CA153

Order Name:
CA 15-3*

 
Useful For:
Determination of DF3 defined antigen in human serum.

Used as an aid in the management of Stage II and III breast cancer patients. Serial testing for patient CA 15-3
assay values should be used in conjunction with other clinical methods for monitoring breast cancer. 
 
Methodology:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName:
Cancer Antigen15-3
 
 
 
Test Code:
CA153

Order Name:
CA 15-3*

 
Collection Specimen Or Container:
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+ reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum (keep in original tube) Refrigerated, 2oC to 8oC 8 hours
Serum Refrigerated, 2oC to 8oC 7 days
Frozen, -20oC 14 days
 
 
 
Test Code:
CA153

Order Name:
CA 15-3*

 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Specimen collected to reported within 2:00 hours (120 mins)
 
Performing Location:
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
CA153

Order Name:
CA 15-3*

 
 
Clinical Information:
The ARCHITECT CA 15-3 assay values are defined by using the 115D8 and DF3 monoclonal antibodies. Monoclonal antibody 115D8, raised against human milk-fat globule membranes, and monoclonal antibody DF3, raised against a membrane enriched fraction of metastatic human breast carcinoma, react with epitopes expressed by a family of high molecular weight glycoproteins designated as polymorphic epithelial mucins (PEMs).

Research studies have indicated that CA 15-3 assay values are frequently elevated in patients with breast cancer. These studies have suggested that the CA 15-3 assay may be of clinical value for monitoring the response of patients undergoing therapy because increasing and decreasing values correlated with disease progression and regression, respectively. Additional published studies have suggested that increasing CA 15-3 assay values in patients at risk for breast cancer recurrence after primary therapy may be indicative of recurrent disease before it can be detected clinically. Elevations of CA 15-3 assay values have been reported in individuals with nonmalignant conditions such as cirrhosis, hepatitis, autoimmune disorders, and benign diseases of the ovary and breast. Non-mammary malignancies in which elevated CA 15-3 assay values have been reported include lung, colon, pancreatic, primary liver, ovarian, cervical, and endometrial. CA 15-3 assay values are not elevated in most normal individuals.

The CA 15-3 assay is not recommended as a screening procedure to detect cancer in the general population; however, use of the CA 15-3 assay as an aid in the management of breast cancer patients has been reported.
 
Reference Value:
0 - 31  U/mL
 
Clinical Reference:
Manufacturer’s Reagent package insert Architect CA 15-3, November 2015, Abbott Laboratories, Diagnostic Division, Abbott Park IL 60064 USA.